BioRestorative Therapies, Inc. - Common Stock (BRTX)
1.1100
+0.0600 (5.71%)
NASDAQ · Last Trade: Nov 25th, 4:03 PM EST
Via Benzinga · November 20, 2025
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · November 20, 2025
Via Benzinga · November 20, 2025
Via Benzinga · November 19, 2025
BioRestorative (BRTX) Earnings Call Transcript
Via The Motley Fool · November 13, 2025
Unusual volume stocks are being observed in Tuesday's session.
Via Chartmill · October 28, 2025
Via Benzinga · October 28, 2025
Via Benzinga · September 22, 2025
Via Benzinga · May 13, 2025

The trading volume of these stocks is deviating from the norm in today's session.
Via Chartmill · February 27, 2025

In today's session, these stocks are experiencing unusual volume.
Via Chartmill · February 25, 2025

Via Benzinga · December 5, 2024

BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial
Via News Direct · November 21, 2024

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market
Via News Direct · November 18, 2024

BioRestorative Therapies shares promising Phase 2 trial results for BRTX-100, showing significant pain reduction and functional improvement in cLDD patients.
Via Benzinga · November 13, 2024

Via Benzinga · October 31, 2024

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?
Via News Direct · September 11, 2024
